Understanding GLP-1 Side Effects: What to Expect

By WPG Research Team · Updated April 6, 2026

Disclosure: Some links on this site are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you. Thank you for supporting our site. For informational purposes only—not medical advice.

On this page

GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are effective weight loss treatments, but like all medications, they come with potential side effects. Understanding what to expect helps you prepare and know when to seek medical attention.

Common Side Effects

The most frequently reported side effects are gastrointestinal in nature. According to FDA prescribing information, these occur in more than 5% of patients:

Gastrointestinal Effects

  • Nausea - Most common, especially during dose increases
  • Diarrhea - Often temporary, improves with time
  • Constipation - May require dietary adjustments
  • Vomiting - Usually related to eating too quickly or too much
  • Abdominal pain - Typically mild to moderate

Quick Facts

Most common side effect
Nausea (40-50% of patients)
Typical improvement timeframe
4-8 weeks
Dose-related
Yes, often worse at higher doses
Reason for discontinuation
~5-7% in clinical trials

Serious Warnings

While rare, some side effects require immediate medical attention.

Seek Immediate Care If You Experience

  • Severe abdominal pain that doesn't go away
  • Signs of pancreatitis (persistent severe pain radiating to back)
  • Signs of allergic reaction (swelling, difficulty breathing)
  • Symptoms of thyroid tumors (lump in neck, hoarseness, difficulty swallowing)
  • Severe hypoglycemia if also taking insulin

Boxed Warning: Thyroid C-Cell Tumors

GLP-1 medications carry an FDA boxed warning about thyroid C-cell tumors observed in rodent studies. While this hasn't been confirmed in humans, these medications are contraindicated in patients with:

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Managing Side Effects

Most side effects can be minimized with proper strategies:

Eating Strategies

  1. Eat smaller portions - Your appetite is reduced; honor that signal
  2. Eat slowly - Take 20+ minutes for meals
  3. Avoid high-fat foods - These can worsen nausea
  4. Stay hydrated - Sip water throughout the day
  5. Stop eating when satisfied - Not when full

Lifestyle Adjustments

  • Don't lie down immediately after eating
  • Avoid alcohol - Can worsen GI symptoms
  • Consider ginger tea - May help with nausea
  • Walk after meals - Aids digestion

Titration Strategy

The standard approach is to start at a low dose and increase gradually. This "slow and low" method significantly reduces side effects. If you're struggling, ask your provider about staying at a lower dose longer before increasing.

When to Contact Your Doctor

Contact your prescriber if you experience:

  • Side effects that don't improve after 2-3 weeks
  • Inability to eat or drink due to nausea
  • Signs of dehydration
  • Severe or worsening symptoms
  • Any symptoms you're concerned about

Your provider may adjust your dose, extend your titration schedule, or prescribe supportive medications to help manage side effects.


This content is based on FDA prescribing information and clinical trial data. Individual experiences may vary. Always consult your healthcare provider with questions about your specific situation.

Frequently Asked Questions

Most common side effects like nausea and digestive issues are worst during the first few weeks and typically improve as your body adjusts. Many patients report significant improvement by week 4-8. If side effects persist beyond 2-3 months or worsen, consult your prescriber.

Yes, many prescribers recommend or prescribe anti-nausea medications like ondansetron (Zofran) during the titration period. Always discuss medication additions with your provider.

Both medications share similar GI side effects. Some studies suggest tirzepatide may have slightly higher rates of diarrhea, while semaglutide may have slightly higher rates of constipation. Individual responses vary significantly.
How we rank + verify

Last verified: April 6, 2026

What we verified: FDA prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro

Sources: FDA labels, clinical trial data, published adverse event reports

Read our full methodology · Advertising disclosure

Related Articles

This content is educational only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting any medication.